Therapeutic advances prevention hepatitis yeast-derived recombinant hepatitis vaccines Viral hepatitis second infectious disease US Hepatitis accounts majority viral hepatitis cases disease self-limiting minimal complications significant number individuals long-term sequelae Research utilizing genetic engineering development yeast-derived recombinant DNA YDR hepatitis vaccines significant advancement control prevention hepatitis recombinant process production unlimited quantities vaccine cost potential threat blood-borne illness Clinical trials various high-risk populations effectiveness safety YDR vaccines questions optimal regimen need periodic revaccination remain unanswered Persons risk hepatitis 